FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	2. Date of Even		3. Issuer Name and Ticker or Tra	ading Symbol				
Rogers Erica J.	Requiring Statement (Month/Day/Year) 04/03/2019		Silk Road Medical Inc [SILK]					
(Last) (First) (Middle) C/O SILK ROAD MEDICAL, INC.			Relationship of Reporting Pers (Check all applicable) X Director	son(s) to Issue	(Moi	Amendment, D nth/Day/Year)	ate of Original Filed	
1213 INNSBRUCK DRIVE			V Officer (give title	Other (spe	cify 6. In		t/Group Filing (Check	
(0)			A below) President and	below)	1	licable Line) Form filed b	by One Reporting Persor	
(Street) SUNNYVALE CA 94089						Form filed b Reporting P	by More than One Person	
(City) (State) (Zip)								
	Table I - No	n-Deriva	tive Securities Beneficial	lly Owned				
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	(D) (Instr. 5)			
Common Stock			96,296	96,296 D				
Common Stock			73,694	I	See Footnote ⁽¹⁾			
(e.			re Securities Beneficially ants, options, convertible		s)			
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Underlying Derivative Security (Instr. 4) Co				6. Nature of Indirect Beneficial Ownership (Instr. 5)	
, , , , , , , , , , , , , , , , , , ,	Expiration D	ate			Conversion or Exercise	Form:	Beneficial Ownership	
	Expiration D	ate	Underlying Derivative Securit		Conversion	Ownership	Beneficial Ownership	
	Expiration Do (Month/Day/\) Date	ate Year) Expiration	Underlying Derivative Securit	Amount or Number of	Conversion or Exercise Price of Derivative	Ownership Form: Direct (D) or Indirect	Beneficial Ownership	
Series C Preferred Stock	Expiration D. (Month/Day/\) Date Exercisable	eate Year) Expiration Date	Underlying Derivative Securit Title Common Stock	Amount or Number of Shares	Conversion or Exercise Price of Derivative Security	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownershi (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy)	Expiration Do (Month/Day/ ¹) Date Exercisable	Expiration Date	Underlying Derivative Securit Title Common Stock Common Stock	Amount or Number of Shares	Conversion or Exercise Price of Derivative Security	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownershi (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy) Employee Stock Option (Right to buy)	Date Exercisable (3)	Expiration Date (2) 12/14/2022	Title Common Stock Common Stock Common Stock	Amount or Number of Shares 9,012 204,110	Conversion or Exercise Price of Derivative Security	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy) Employee Stock Option (Right to buy) Employee Stock Option (Right to buy)	Date Exercisable (2) (3)	Expiration Date (2) 12/14/2022 12/24/2024	Title Common Stock Common Stock Common Stock Common Stock Common Stock	Amount or Number of Shares 9,012 204,110 61,728	Conversion or Exercise Price of Derivative Security (2) 1.38 1.46	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy)	Date Exercisable (2) (3) (4)	Expiration Date (2) 12/14/2022 12/24/2024 12/03/2025	Title Common Stock	Amount or Number of Shares 9,012 204,110 61,728 143,290	Conversion or Exercise Price of Derivative Security (2) 1.38 1.46 1.6	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy)	Date Exercisable (2) (3) (4) (5)	Expiration Date (2) 12/14/2022 12/03/2025 08/04/2026	Title Common Stock	Amount or Number of Shares 9,012 204,110 61,728 143,290 259,259	Conversion or Exercise Price of Derivative Security (2) 1.38 1.46 1.6	Ownership Form: Direct (D) or Indirect (I) (Instr. 5) I D D D	Beneficial Ownershi (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy)	Date Exercisable (2) (3) (4) (5)	Expiration Date (2) 12/14/2022 12/03/2025 08/04/2026 11/30/2027	Title Common Stock	Amount or Number of Shares 9,012 204,110 61,728 143,290 259,259 74,074	Conversion or Exercise Price of Derivative Security (2) 1.38 1.46 1.6 1.6 6.11	Ownership Form: Direct (D) or Indirect (I) (Instr. 5) I D D D D	Beneficial Ownershi (Instr. 5)	
Series C Preferred Stock Employee Stock Option (Right to buy) Employee Stock Option (Right to buy)	Date Exercisable (2) (3) (4) (5) (6)	Expiration Date (2) 12/14/2022 12/03/2025 08/04/2026 11/30/2027	Title Common Stock	Amount or Number of Shares 9,012 204,110 61,728 143,290 259,259 74,074 366,666	Conversion or Exercise Price of Derivative Security (2) 1.38 1.46 1.6 1.6 1.11	Ownership Form: Direct (D) or Indirect (I) (Instr. 5) I D D D D D D	Beneficial Ownershi (Instr. 5)	

Explanation of Responses:

- 1. These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace/Rogers Family Trust (the "Surace/Rogers Family Trust").
- 2. The Series C Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration
- 3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- 4. One forty-eighth of the shares subject to the option vested on January 3, 2016 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- 5. One forty-eighth of the shares subject to the option vested on September 4, 2016 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date
- 6. One forty-eighth of the shares subject to the option vested on September 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date 7. All of the shares subject to the option shall vest upon the earlier of a change in control of the Issuer or the two year anniversary of the initial public offering of the Issuer's Common Stock, subject to the
- Reporting Person continuing as a service provider through such date.
- 8. All of the shares subject to this warrant are fully vested and exercisable as of the date hereof.
- 9. This warrant is held by the Surace/Rogers Family Trust.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Mhairi Jones, by power of <u>attorney</u>

04/03/2019

** Signature of Reporting Person

Date

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Silk Road Medical, Inc. (the "**Company**"), hereby constitutes and appoints Lucas W. Buchanan, Mhairi Jones and Nga T. Van, and each of them, the undersigned's true and lawful attorney-in-fact, to:

- 1. Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation of the SEC;
- 2. Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Exchange Act and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 3. Do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19 day of March, 2019.

Signature: <u>/s/ Erica J. Rogers</u>

Print Name: <u>Erica J. Rogers</u>